US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Monday reported positive topline results from a Phase 2 study evaluating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis.

The trial met its primary endpoint, showing a statistically significant increase in the proportion of participants achieving at least a 75% reduction in the Eczema Area and Severity Index at Week 16 compared with placebo. Placebo-adjusted response rates were 38.7% for the low dose, 51.9% for the mid dose, and 49.4% for the high dose.

Tilrekimig is an investigational trispecific antibody targeting interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP), with potential as a once-monthly therapy for Type 2 inflammatory diseases including atopic dermatitis, asthma, and chronic obstructive pulmonary disease. In the trial, the treatment was well tolerated with a favourable safety profile and adverse event rates comparable to placebo.

Based on the results, Pfizer plans to advance tilrekimig into Phase 3 development, with a pivotal study in atopic dermatitis expected to begin this year. The company is also evaluating the therapy in Phase 2 trials for asthma and in a Phase 2b/3 study for chronic obstructive pulmonary disease.